Keywords: Breast cancer, Sanofi-Aventis, AstraZeneca, GlaxoSmithKline, Roche, Pfizer, Decision Resources, Avastin

Combined sales of seven emerging therapies for breast cancer, including from Sanofi-Aventis and AstraZeneca, will total nearly $5 billion by 2019

Article | 29 October 2010

Print This

Through 2019, the combined sales of seven new therapies for the treatment of breast cancer will total nearly $5 billion in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in